A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease

Akiko Hori, Yoshinobu Kanda, Susumu Goyama, Yasushi Onishi, Yukiko Komeno, Kinuko Mitani, Yukiko Kishi, Seishi Ogawa, Osamu Imataki, Shigeru Chiba, Rie Kojima, Tamae Hamaki, Michiyo Sakiyama, Masahiro Kami, Atsushi Makimoto, Ryuji Tanosaki, Yoichi Takaue, Hisamaru Hirai

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

This prospective study evaluates the safety and efficacy of pravastatin for the treatment of chronic graft-versus-host disease (GVHD). We included 18 patients with refractory chronic GVHD. Oral pravastatin was started at 10 mg/day, and the dose was increased up to 40 mg/day in 4 weeks. This maximum dose was administered over 8 weeks. There were no severe adverse events caused by pravastatin. A clinical response was observed in the skin score in two patients, mouth score in five patients, eye score in two patients, liver score in three patients, platelet count score in one patient, and weight loss in two patients. The overall response rate was 28%. Immunophenotypic analyses showed that T-helper (Th) 1 cells were dominant in all but one patient before treatment and that the Th1/Th2 ratio tended to be lower in the responders than in the nonresponders. A randomized controlled trial is warranted to evaluate the efficacy of pravastatin against chronic GVHD.

Original languageEnglish
Pages (from-to)372-374
Number of pages3
JournalTransplantation
Volume79
Issue number3
DOIs
Publication statusPublished - 2005 Feb 15
Externally publishedYes

    Fingerprint

Keywords

  • Chronic graft-versus-host disease
  • Pravastatin
  • Treatment

ASJC Scopus subject areas

  • Transplantation

Cite this

Hori, A., Kanda, Y., Goyama, S., Onishi, Y., Komeno, Y., Mitani, K., Kishi, Y., Ogawa, S., Imataki, O., Chiba, S., Kojima, R., Hamaki, T., Sakiyama, M., Kami, M., Makimoto, A., Tanosaki, R., Takaue, Y., & Hirai, H. (2005). A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease. Transplantation, 79(3), 372-374. https://doi.org/10.1097/01.TP.0000151001.64189.1D